HAEMONETICS CORP — Director's Dealing 2023

Jun 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-06-29

Reporting Person: Simon, Christopher (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-29	Common Stock	M	196746	$28.615	Acquired	414113	Direct
2023-06-29	Common Stock	F	117667	$84.84	Disposed	296446	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-29	Non-qualified Stock Option (Right to Buy)	$28.615	M	196746	Disposed	2023-06-29	Common Stock (196746)	Direct

Footnotes

F1: Represents an automatic exercise of options granted in 2016 and scheduled to expire after June 29, 2023, as reflected in this Form 4.

F2: This number includes unvested restricted stock units previously reported.

F3: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.